{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:24:20Z","timestamp":1782437060659,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jad.2018.06.043","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T13:12:05Z","timestamp":1530969125000},"page":"425-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study"],"prefix":"10.1016","volume":"241","author":[{"given":"Joseph R.","family":"Calabrese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Amatniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8279-0004","authenticated-orcid":false,"given":"Brian","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1203-123X","authenticated-orcid":false,"given":"Pamela P.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Such","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretta","family":"Nyilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2018.06.043_bib0001","series-title":"Full Prescribing Information","year":"2016"},{"key":"10.1016\/j.jad.2018.06.043_bib0002","series-title":"Practice Guideline for the Treatment of Patients with Bipolar Disorder","article-title":"second ed","year":"2002"},{"key":"10.1016\/j.jad.2018.06.043_bib0003","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.jad.2018.06.043_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0447.2008.01310.x","article-title":"Side-effects of antipsychotic medication and health-related quality of life in schizophrenia","author":"Bebbington","year":"2009","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.jad.2018.06.043_bib0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4088\/JCP.16m11201","article-title":"Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study","volume":"78","author":"Calabrese","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0006","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/nedt.2006.2.4.427","article-title":"A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder","volume":"2","author":"Citrome","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2018.06.043_bib0007","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14740338.2014.906579","article-title":"Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review","volume":"13","author":"De Hert","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2018.06.043_bib0008","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.jad.2018.06.043_bib0009","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1176\/appi.ajp.160.1.112","article-title":"Obesity as a correlate of outcome in patients with bipolar I disorder","volume":"160","author":"Fagiolini","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1399-5618.2005.00234.x","article-title":"Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians","volume":"7","author":"Fagiolini","year":"2005","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2018.06.043_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-859X-8-16","article-title":"Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review","volume":"8","author":"Fountoulakis","year":"2009","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0012","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","article-title":"Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review","volume":"28","author":"Gao","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.06.043_bib0013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1399-5618.2011.00932.x","article-title":"The burden of obesity among adults with bipolar disorder in the United States","volume":"13","author":"Goldstein","year":"2011","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2018.06.043_bib0014","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2018.06.043_bib0015","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2018.06.043_bib0016","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4088\/JCP.v65n0709","article-title":"Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects","volume":"65","author":"Hofer","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jad.2008.05.014","article-title":"Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study","volume":"112","author":"Keck","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2018.06.043_bib0018","doi-asserted-by":"crossref","first-page":"844","DOI":"10.4088\/JCP.08m04045","article-title":"Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania","volume":"70","author":"Keck","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0019","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.4088\/JCP.v68n1003","article-title":"Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo","volume":"68","author":"Keck","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0020","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1399-5618.2004.00138.x","article-title":"Burden of general medical conditions among individuals with bipolar disorder","volume":"6","author":"Kilbourne","year":"2004","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2018.06.043_bib0021","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","article-title":"Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence","volume":"19","author":"Lambert","year":"2004","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12888-017-1213-6","article-title":"Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications","volume":"17","author":"Llorca","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0023","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4088\/JCP.v63n0306","article-title":"Correlates of overweight and obesity in 644 patients with bipolar disorder","volume":"63","author":"McElroy","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.jad.2018.06.043_bib0024","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.clinthera.2010.01.022","article-title":"Aripiprazole for the maintenance treatment of bipolar I disorder: a review","volume":"32","author":"McIntyre","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2018.06.043_bib0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/14656566.8.7.1001","article-title":"Aripiprazole: pharmacology and evidence in bipolar disorder","volume":"8","author":"McIntyre","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jad.2018.06.043_bib0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0027","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/NDT.S43113","article-title":"Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depression","volume":"9","author":"Penders","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2018.06.043_bib0028","doi-asserted-by":"crossref","first-page":"15039","DOI":"10.1038\/npjschz.2015.39","article-title":"Aripiprazole once-monthly 400mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study","volume":"1","author":"Peters-Strickland","year":"2015","journal-title":"NPJ Schizophr"},{"key":"10.1016\/j.jad.2018.06.043_bib0029","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/YIC.0000000000000168","article-title":"Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY","volume":"32","author":"Potkin","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.06.043_bib0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.biopsych.2010.01.015","article-title":"Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder","volume":"68","author":"Quiroz","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0031","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1176\/appi.ajp.162.7.1281","article-title":"Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial","volume":"162","author":"Tohen","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"1\u201346","key":"10.1016\/j.jad.2018.06.043_bib0032","first-page":"47","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0033","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/104012371102300107","article-title":"Cardiovascular morbidity and mortality in bipolar disorder","volume":"23","author":"Weiner","year":"2011","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.06.043_bib0034","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jad.2006.08.009","article-title":"Atypical antipsychotics related metabolic syndrome in bipolar patients","volume":"98","author":"Yumru","year":"2007","journal-title":"J. Affect. Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718305895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718305895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:24:00Z","timestamp":1759022640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718305895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"alternative-id":["S0165032718305895"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2018.06.043","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2018.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}